Table 1.
Format | Time Points (Days) | Reported Efficiency |
Refs | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chemically Defined |
Monolayer (2D) |
Basic Monolayer |
D-2 | D-1 | D0 | D1 | D3 | D4 | D5 | D7 | D8 | D14 | ≤90% | Paige et al., 2010 |
100ng/ml WNT3A* |
100ng/ml Activin A |
10ng/ml BMP-4 | 200ng/ml DKK-1* | |||||||||||
Matrix Sandwich |
D-2 | D-1 | D0 | D1 | D3 | D4 | D5 | D7 | D8 | D14 | ≤98% | Zhang et al., 2012 | ||
Matrigel Overlay |
Matrigel Overlay 100ng/ml Activin A |
10ng/ml BMP-4 5ng/ml bFGF |
||||||||||||
Small Molecules |
D-2 | D-1 | D0 | D1 | D3 | D4 | D5 | D7 | D8 | D14 | ≤98% | Lian et al., 2012a | ||
12 M CHIR99021 µg/ml Insulin* |
5 µM IWP-2 or IWP-4 |
|||||||||||||
EB (3D) |
Staged, defined |
D-2 | D-1 | D0 | D1 | D3 | D4 | D5 | D7 | D8 | D14 | 30–60% | Kattman et al., 2011 | |
0.4ng/ml BMP-4 |
0–12ng/ml Activin A 2.5–20 ng/ml BMP-4 5ng/ml bFGF |
150ng/ml DKK-1 10ng/mlVEGF |
10ng/ml VEGF 5ng/ml bFGF | |||||||||||
5.4 M SB-431542* 0.6µM Dorsomorphin* |
||||||||||||||
Chemically Undefined | Undefined | D-2 | D-1 | D0 | D1 | D3 | D4 | D5 | D7 | D8 | D14 | 0.1–10% | Kehat et al., 2001 | |
5–20% FBS or KSR | ||||||||||||||
Co-culture(2D) | D-2 | D-1 | D0 | D1 | D3 | D4 | D5 | D7 | D8 | D14 | ≤25% | Mummery et al, 2007 | ||
END2 conditioned medium |
D2 and D1 refer to days prior to differentiation. D0-D14 refer to days at time of differentiation.
FBS: Fetal Bovine Serum. KSR: Knockout Serum replacement.
Refers to reported modifications of the original protocols aimed to enhance the cardiogenic potential of PSC.